Médea Hegyköziné Dr Veszelka

Dr. Médea Hegyköziné Dr Veszelka


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2024 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
ANAndrás Nagy
András Nagy
Denise BörzseiDenise Börzsei
Denise Börzsei
AHAlexandra Hoffmann
Alexandra Hoffmann
STSzilvia Török
Szilvia Török
MVMédea Hegyköziné Dr Veszelka
Médea Hegyköziné Dr Veszelka
Renáta SzabóRenáta Szabó
Renáta Szabó
While oncotherapy has made rapid progress in recent years, side effects of anti-cancer drugs and treatments have also come to the fore. These side effects include cardiotoxicity, which can cause irreversible cardiac damages with long-term morbidity and mortality. Despite the continuous in-depth research on anti-cancer drugs, an improved knowledge of the underlying mechanisms of cardiotoxicity are necessary for early detection and management of cardiac risk. Although most reviews focus on the cardiotoxic effect of a specific individual chemotherapeutic agent, the aim of our review is to provide comprehensive insight into various agents that induced cardiotoxicity and their underlying mechanisms. Characterization of these mechanisms are underpinned by research on animal models and clinical studies. In order to gain insight into these complex mechanisms, we emphasize the role of inflammatory processes and oxidative stress on chemotherapy-induced cardiac changes. A better understanding and identification of the interplay between chemotherapy and inflammatory/oxidative processes hold some promise to prevent or at least mitigate cardiotoxicity-associated morbidity and mortality among cancer survivors.

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
Denise BörzseiDenise Börzsei
Denise Börzsei
JSJudith Sebestyén
Judith Sebestyén
Renáta SzabóRenáta Szabó
Renáta Szabó
ZLZelma Nadin Lesi
Zelma Nadin Lesi
APAndrea Pálszabó
Andrea Pálszabó
APAnikó Pósa
Anikó Pósa
According to a widely accepted theory, oxidative stress is considered to be the number one trigger of aging‐associated degenerative processes including cardiovascular diseases. In the context of aging‐research, resveratrol receives special attention with its surprising number of health benefits. The aim of our study was to examine the anti‐inflammatory and antioxidant effects of this dietary polyphenol in aging rat heart. 20‐month‐old female and male Wistar rats were divided into control (untreated) and resveratrol‐treated groups. Resveratrol was administered at a dose of 0.05 mg/ml for 12 weeks dissolved in drinking water, while the control rats received ad libitum water. Cardiac level of reactive oxygen species (ROS), nuclear factor kappa B (NFκB), tumor necrosis factor alpha (TNF‐α), and glutathione (GSH) parameters, as well as the activity of myeloperoxidase (MPO) and heme oxygenase (HO) enzymes were detected. Together with the biochemical measurements, hearts were isolated and used for an exposure of ischemic‐reperfusion injury via Langendorff perfusion system. 12 week of resveratrol treatment suppressed the age‐related inflammatory pathways including the expression of TNF‐α, NFκB, and the activity of MPO while intensified the endogenous antioxidant defenses through the induction of GSH and HO system. Presumably, as a result of these processes, the necrotic area of the heart in response to an acute injury was also significantly reduced in the resveratrol‐treated groups. Our findings confirmed that resveratrol has cardioprotective effects at several points by counteracting the aging‐associated cellular malfunctions in the heart.

28 April 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
STSzilvia Török
Szilvia Török
NANikoletta Almási
Nikoletta Almási
MVMédea Hegyköziné Dr Veszelka
Médea Hegyköziné Dr Veszelka
Denise BörzseiDenise Börzsei
Denise Börzsei
Renáta SzabóRenáta Szabó
Renáta Szabó
CVCsaba Varga
Csaba Varga
Inflammatory bowel diseases (IBD) are chronic, inflammatory disorders of the gastrointestinal (GI) system, which have become a global disease over the past few decades. It has become increasingly clear that oxidative stress plays a role in the pathogenesis of IBD. Even though several effective therapies exist against IBD, these might have serious side effects. It has been proposed that hydrogen sulfide (H2S), as a novel gasotransmitter, has several physiological and pathological effects on the body. Our present study aimed to investigate the effects of H2S administration on antioxidant molecules in experimental rat colitis. As a model of IBD, 2,4,6-trinitrobenzenesulfonic acid (TNBS) was used intracolonically (i.c.) to induce colitis in male Wistar–Hannover rats. Animals were orally treated (2 times/day) with H2S donor Lawesson’s reagent (LR). Our results showed that H2S administration significantly decreased the severity of inflammation in the colons. Furthermore, LR significantly suppressed the level of oxidative stress marker 3-nitrotyrosine (3-NT) and caused a significant elevation in the levels of antioxidant GSH, Prdx1, Prdx6, and the activity of SOD compared to TNBS. In conclusion, our results suggest that these antioxidants may offer potential therapeutic targets and H2S treatment through the activation of antioxidant defense mechanisms and may provide a promising strategy against IBD.

1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
Renáta SzabóRenáta Szabó
Renáta Szabó
AHAlexandra Hoffmann
Alexandra Hoffmann
Denise BörzseiDenise Börzsei
Denise Börzsei
KKKrisztina Kupai
Krisztina Kupai
MVMédea Hegyköziné Dr Veszelka
Médea Hegyköziné Dr Veszelka
CVCsaba Varga
Csaba Varga
Advanced age is an independent risk factor for cardiovascular diseases, which might be further exacerbated by estrogen deficiency. Hormone replacement therapy (HRT) decreases cardiovascular risks and events in postmenopausal women; however, its effects are not fully elucidated in older individuals. Thus, the aim of our study is to examine the impact of HRT on oxidant/antioxidant homeostasis and cardiac remodeling. In our experiment, control (fertile) and aging (~20‐month‐old) female Wistar rats were used. Aging rats were further divided into estrogen‐ (E2, 0.1 mg/kg/day per os) or raloxifene‐ (RAL, 1.0 mg/kg/day per os) treated subgroups. After 2 weeks of treatment, cardiac heme oxygenase (HO) activity, total glutathione (GSH) content, matrix metalloproteinase‐2 (MMP‐2) activity, and the concentrations of collagen type I and tissue inhibitor of metalloproteinase (TIMP‐2), as well as the infarct size, were determined. The aging process significantly decreased the antioxidant HO activity and GSH content, altered the MMP‐2/TIMP‐2 signaling, and resulted in an excessive collagen accumulation, which culminated in cardiovascular injury. However, 2 weeks of either E2 or RAL treatment enhanced the antioxidant defense mechanisms and attenuated cardiac remodeling related to aging. Our findings clearly show that 2‐week‐long HRT is a potential intervention to bias successful cardiovascular aging via reducing oxidative damage and cardiovascular dysfunction.

6 October 2015 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
KKKrisztina Kupai
Krisztina Kupai
Renáta SzabóRenáta Szabó
Renáta Szabó
MVMédea Hegyköziné Dr Veszelka
Médea Hegyköziné Dr Veszelka
AAAmin Al Awar
Amin Al Awar
STSzilvia Török
Szilvia Török
CVCsaba Varga
Csaba Varga
It is well established that physical exercise continues to be one of the most valuable forms of non-pharmacological therapy against diabetes mellitus; however, the precise mechanism remains unknown. The aim of this study was to investigate the cardioprotective effect of voluntary exercise in the Goto-Kakizaki type 2 diabetic rat heart against ischemia–reperfusion injury and to clarify its biochemical background, focusing on the nitric oxide synthase/heme oxygenase system. One group of male Goto-Kakizaki rats were allowed voluntary exercise, whereas others were kept sedentary for 6 weeks. At the end of the 6th week the hearts were isolated from both groups and subjected to 45-min coronary occlusion followed by 120-min reperfusion. The infarct size was evaluated by means of triphenyltetrazolium chloride staining. The cardiac and aortic nitric oxide synthase/heme oxygenase activities, plasma leptin and glucose concentrations were also assessed. The sedentary state prior to the ischemia–reperfusion injury was associated with a significantly higher infarct size (24.56 ± 2.21 vs. 16.66 ± 1.87 %) as compared with that in the voluntary wheel-running group. Exercise altered the constitutive nitric oxide synthase activity; an enhancement was evident in the cardiac (42.5 ± 2.72 vs. 75.6 ± 13.34 pmol/min/mg protein) and aortic tissues (382.5 ± 66.57 vs. 576.9 ± 63.16 pmol/min/mg protein). Exercise lead to a higher heme oxygenase activity (0.68 ± 0.08 vs. 0.92 ± 0.04 nmol bilirubin/h/mg protein) in the diabetic rat hearts. Exercise was associated with lower plasma leptin (192.23 ± 7.22 vs. 169.65 ± 4.6 ng/L) and blood glucose (19.61 ± 0.76 vs. 14.58 ± 0.88 mmol/L) levels. These results indicate the beneficial role of exercise against myocardial ischemia–reperfusion injury in diabetic rats. These observations in experimental diabetes suggest that the cytoprotective mechanism of exercise involves modulation of the nitric oxide synthase/heme oxygenase system and metabolic parameters that may be responsible for cardioprotection.

28 February 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
Denise BörzseiDenise Börzsei
Denise Börzsei
Renáta SzabóRenáta Szabó
Renáta Szabó
AHAlexandra Hoffmann
Alexandra Hoffmann
MVMédea Hegyköziné Dr Veszelka
Médea Hegyköziné Dr Veszelka
IPImre Pavo Pavo
Imre Pavo Pavo
APAnikó Pósa
Anikó Pósa
Selective estrogen receptor modulators (SERMs) were discovered in the mid-1900s in connection with estrogen-related pathological conditions. They were developed to antagonize the adverse effects of estrogen and have been shown to be effective against postmenopausal disorders manifested by estrogen deficiency. Raloxifene (RAL), one of the most widely used SERMs, expresses estrogen-like effects on bones, while it is found to be an antagonist on breast and uterus. RAL has multiple beneficial effects throughout the body, including antioxidant and anti-inflammatory properties, because of which it gains particular attention. Additionally, previous studies have revealed that RAL is an efficient modulator of heme-oxygenase (HO) expression. HO, through its general activity, participates in comprehensive cell defense processes, thus the induction of HO by RAL administration indicates a major role in its therapeutic efficacy. In this review, we compile the current knowledge about the overall metabolic, neurocognitive, and cardiovascular effects of RAL involving the cytoprotective HO-system.